Generalizability of trial criteria on amyloid-lowering therapy against Alzheimer’s disease to individuals with mild cognitive impairment or early Alzheimer’s disease in the general population
European Journal of Epidemiology · 2025
DOI: 10.1007/s10654-025-01220-1 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Epidemiology, 2025. Verfasst von Jacqueline J Claus und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology, Erasmus MC, Rotterdam, The Netherlands. Hauptthemen laut MEDLINE: Alzheimer Disease, Cognitive Dysfunction, Amyloid beta-Peptides, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hartstichting, ZonMw, Alzheimer's Association.
Themen: Demenz
Abstract (Originalsprache)
Treatment with anti-amyloid-β monoclonal antibodies slowed cognitive decline in recent RCTs in patients with mild cognitive impairment (MCI) and early dementia due to Alzheimer’s disease (AD). However, stringent trial eligibility criteria may affect generalisability to clinical practice. We extracted eligibility criteria for trials of aducanumab, lecanemab and donanemab, and applied these to participants with MCI and early clinical AD dementia from the population-based Rotterdam Study. Participants underwent questionnaires, genotyping, brain-MRI, cognitive testing, and cardiovascular assessment. We determined amyloid status using a validated prediction model based on age and APOE-g enotype. Of 968 participants (mean age: 75 years, 56% women), 779 had MCI and 189 dementia. Across trials, around 40% of participants would be ineligible because of predicted amyloid negativity. At least one clinical exclusion criterion was present in 76.3% of participants for aducanumab, 75.8% for lecanemab, and 59.8% for donanemab. Common criteria were cardiovascular disease (35.2%), anticoagulant (31.2%), psychotropic or immunological medication use (20.4%), anxiety or depression (15.9%), or lack of social support (15.6%). One-third were ineligible based on brain-MRI findings alone, similar across trials and predominantly due to cerebral small-vessel disease. Combining amyloid, clinical, and imaging criteria, eligibility ranged from 9% (95% CI:7.0-11.1) for aducanumab, 8% (6.2–9.9) lecanemab to 15% (12.4–17.5) for donanemab. Findings from recent RCTs reporting protective effects of monoclonal antibodies against amyloid-β are applicable to less than 15% of community-dwelling individuals with MCI or early AD. These findings underline that evidence for drug efficacy and safety is lacking for the vast majority of patients with MCI/AD in routine clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Epidemiology, Erasmus MC, Rotterdam, The Netherlands.
- Department of Radiology & Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands.
- Department of General Practice, Erasmus MC, Rotterdam, The Netherlands.
- Department of Neurology, Erasmus MC, Rotterdam, The Netherlands.
- Department of Epidemiology, Erasmus MC, Rotterdam, The Netherlands. f.j.wolters@erasmusmc.nl.
- Department of Radiology & Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands. f.j.wolters@erasmusmc.nl.
Förderung
- Hartstichting
- ZonMw
- Alzheimer's Association
Zitieren
APA
Claus, J. J., Vom Hofe, I., van Ijlzinga Veenstra, A., Licher, S., Seelaar, H., de Jong, F. J., Neitzel, J., Vernooij, M. W., Ikram, M. A., & Wolters, F. J. (2025). Generalizability of trial criteria on amyloid-lowering therapy against Alzheimer’s disease to individuals with mild cognitive impairment or early Alzheimer’s disease in the general population. European Journal of Epidemiology. https://doi.org/10.1007/s10654-025-01220-1
Vancouver
Claus JJ, Vom Hofe I, van Ijlzinga Veenstra A, Licher S, Seelaar H, de Jong FJ, et al. Generalizability of trial criteria on amyloid-lowering therapy against Alzheimer’s disease to individuals with mild cognitive impairment or early Alzheimer’s disease in the general population. European Journal of Epidemiology. 2025. doi:10.1007/s10654-025-01220-1
BibTeX
@article{Claus2025,
author = {Claus, Jacqueline J and Vom Hofe, Ilse and van Ijlzinga Veenstra, Annekee and Licher, Silvan and Seelaar, Harro and de Jong, Frank J and Neitzel, Julia and Vernooij, Meike W and Ikram, M Arfan and Wolters, Frank J},
title = {Generalizability of trial criteria on amyloid-lowering therapy against Alzheimer’s disease to individuals with mild cognitive impairment or early Alzheimer’s disease in the general population},
journal = {European Journal of Epidemiology},
year = {2025},
doi = {10.1007/s10654-025-01220-1}
}
EUVIMED